{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_7465454_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"061-918-002-510-672","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10710,"type":"PATENT","title":"University of Colorado Boulder Patent Portforlio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7179,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8227,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"University Colorado\" \"univ* Colorado\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4836
Search Applicants and Owners separately:\"University Colorado\" \"univ* Colorado\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4836
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein X6 is a proline."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the fusion protein comprises at least two or more cancer antigens expressed by the cancer."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the fusion protein comprises at least one or more immunogenic domains of one or more cancer antigens expressed by the cancer."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is an antigen expressed by a cancer selected from the group consisting of: melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias and metastatic cancers thereof."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is wild-type or mutant protein encoded by a ras gene."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the cancer antigen is wild-type or mutant protein encoded by a ras gene selected from the group consisting of: K-ras, N-ras and H-ras genes."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the ras gene encodes a Ras protein with single or multiple mutations."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen comprises fragments of at least 5-9 contiguous amino acid residues of a wild-type Ras protein containing amino acid positions 12, 13, 59 or 61 relative to the wild-type Ras protein, wherein the amino acid residues at positions 12, 13, 59 or 61 are mutated with respect to the wild-type Ras protein."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen consists of a fusion protein construct comprising multiple domains, wherein each domain consists of a peptide from an oncoprotein, the peptide consisting of at least 4 amino acid residues flanking either side of and including a mutated amino acid that is found in the protein, wherein the mutation is associated with tumorigenicity."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 11, wherein the fusion protein construct consists of at least one peptide that is fused in frame with another mutated cancer antigen, wherein the peptide is selected from the group consisting of:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer; and\nii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof the peptide consisting of between two and six amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof;\nwherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2—X3—X4—X5—X6;\n\n(1) wherein M is methionine;\n(2) wherein X2 is any amino acid except glycine, proline, lysine or arginine;\n(3) wherein X3 is any amino acid except methionine, lysine or arginine;\n(4) wherein X4 is any amino acid except methionine, lysine or arginine;\n(5) wherein X5 is any amino acid except methionine, lysine or arginine; and\n(6) wherein X6 is any amino acid except methionine.\n
a) a peptide comprising at least from positions 8-16 of SEQ ID NO:3, wherein the amino acid residue at position 12 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3;\n
b) a peptide comprising at least from positions 9-17 of SEQ ID NO:3, wherein the amino acid residue at position 13 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3;\n
c) a peptide comprising at least from positions 55-63 of SEQ ID NO:3, wherein the amino acid residue at position 59 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; and\n
d) a peptide comprising at least from positions 57-65 of SEQ ID NO:3, wherein the amino acid residue at position 61 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 12, wherein the mutated cancer antigen is a Ras protein comprising at least one mutation relative to a wild-type Ras protein sequence."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein a yeast cell or yeast spheroplast used to prepare the yeast vehicle was transformed with a recombinant nucleic acid molecule encoding the fusion protein such that the fusion protein is recombinantly expressed by the yeast cell or yeast spheroplast."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the yeast cell or yeast spheroplast that recombinantly expresses the fusion protein is used to produce a yeast vehicle comprising a yeast cytoplast, a yeast ghost, or a subcellular yeast membrane extract or fraction thereof."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is from a non-pathogenic yeast."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kiuveromyces, Hansenula, Candida and Pichia."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein Saccharomyces is S. cerevisiae. "],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition is administered to the respiratory tract."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition is administered by a parenteral route of administration."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition further comprises dendritic cells or macrophages, wherein the yeast vehicle expressing the fusion protein is delivered to dendritic cells or macrophages ex vivo and wherein the dendritic cell or macrophage containing the yeast vehicle expressing the fusion protein is administered to the animal."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the dendritic cell or the yeast vehicle has been additionally loaded with free antigen."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the animal has a cancer selected from the group consisting of brain cancer, lung cancer, breast cancer, melanoma, and renal cancer."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administration of the composition occurs after surgical resection of a tumor from the animal."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administration of the composition occurs after surgical resection of a tumor from the animal and after administration of non-myeloablative allogeneic stem cell transplantation."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administration of the composition occurs after surgical resection of a tumor from the animal, after administration of non-myeloablative allogeneic stem cell transplantation, and after allogeneic donor lymphocyte infusion."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["A method to inhibit tumor growth in an animal that has cancer, comprising administering to an animal a composition that inhibits tumor growth in the animal, wherein the composition comprises:\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is EGF-R."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is MART1."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is VHL (von Hippel's Lindau protein)."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer; and\nii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof the peptide consisting of between two and six amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof;\nwherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2—X3—X4—X5—X6;\n\n(1) wherein M is methionine;\n(2) wherein X2 is any amino acid except glycine, proline, lysine or arginine;\n(3) wherein X3 is any amino acid except methionine, lysine or arginine;\n(4) wherein X4 is any amino acid except methionine, lysine or arginine;\n(5) wherein X5 is any amino acid except methionine, lysine or arginine; and\n(6) wherein X6 is any amino acid except methionine.\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a valine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a cysteine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with an aspartic acid residue as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is wild-type or mutant protein encoded by a ras gene."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a valine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a cysteine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with an aspartic acid residue as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is EGF-R."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is MART1."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the cancer antigen is VHL (von Hippel's Lindau protein)."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein a yeast cell or yeast spheroplast used to prepare the yeast vehicle was transformed with a recombinant nucleic acid molecule encoding the cancer antigen such that the cancer antigen is recombinantly expressed by the yeast cell or yeast spheroplast."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, wherein the yeast cell or yeast spheroplast that recombinantly expresses the cancer antigen is used to produce a yeast vehicle comprising a yeast cytoplast, a yeast ghost, or a subcellular yeast membrane extract or fraction thereof."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the yeast vehicle is from a non-pathogenic yeast."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kiuveromyces, Hansenula, Candida and Pichia. "],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 46, wherein Saccharomyces is S. cerevisiae. "],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["A method to increase survival or reduce tumor burden in an animal that has cancer, comprising administering to an animal a composition that increases survival of the animal or reduces tumor burden in the animal, wherein the composition comprises:\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["A method to inhibit tumor growth in an animal that has cancer, comprising administering to an animal a composition that inhibits tumor growth in the animal, wherein the composition comprises:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer; and\nii) a peptide comprising an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1), wherein said peptide is linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and 200 amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof.\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["A method to increase survival, reduce tumor burden, or inhibit tumor growth in an animal that has cancer, comprising administering to an animal a composition that increases survival of the animal or reduces tumor burden in the animal, wherein the composition comprises:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer; and\nii) a peptide comprising an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1), wherein said peptide is linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and 200 amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof.\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein X6 is a proline."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the peptide comprises an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the ras gene encodes a Ras protein with single or multiple mutations."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen comprises fragments of at least 5-9 contiguous amino acid residues of a wild-type Ras protein containing amino acid positions 12, 13, 59 or 61 relative to the wild-type Ras protein, wherein the amino acid residues at positions 12, 13, 59 or 61 are mutated with respect to the wild-type Ras protein."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen consists of a fusion protein construct comprising multiple domains, wherein each domain consists of a peptide from a Ras protein, the peptide consisting of at least 4 amino acid residues flanking either side of and including a mutated amino acid that is found in the protein, wherein the mutation is associated with tumorigenicity."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen consists of a fusion protein construct consisting of at least one peptide from a Ras protein that is fUsed in frame with another mutated cancer antigen, wherein the peptide is selected from the group consisting of:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer, wherein the cancer antigen is a mutant protein encoded by a ras gene selected from the group consisting of: K-ras, N-ras and H-ras genes; and\nii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and 200 amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof;\nwherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2—X3—X4—X5—X6;\n\n(1) wherein M is methionine;\n(2) wherein X2 is any amino acid except glycine, proline, lysine or arginine;\n(3) wherein X3 is any amino acid except methionine, lysine or arginine;\n(4) wherein X4 is any amino acid except methionine, lysine or arginine;\n(5) wherein X5 is any amino acid except methionine, lysine or arginine; and\n(6) wherein X6 is any amino acid except methionine.\n
a) a peptide comprising at least from positions 8-16 of SEQ ID NO:3, wherein the amino acid residue at position 12 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3;\n
b) a peptide comprising at least from positions 9-17 of SEQ ID NO:3, wherein the amino acid residue at position 13 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3;\n
c) a peptide comprising at least from positions 55-63 of SEQ ID NO:3, wherein the amino acid residue at position 59 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; and\n
d) a peptide comprising at least from positions 57-65 of SEQ ID NO:3, wherein the amino acid residue at position 61 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 56, wherein the mutated cancer antigen is a Ras protein comprising at least one mutation relative to a wild-type Ras protein sequence."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a valine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 58, wherein the peptide comprises an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a cysteine as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 60, wherein the peptide comprises an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with a leucine as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with an aspartic acid residue as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamic acid at position 61 is substituted with an arginine as compared to a wild-type Ras."],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 62, wherein the peptide comprises an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein a yeast cell or yeast spheroplast used to prepare the yeast vehicle was transformed with a recombinant nucleic acid molecule encoding the cancer antigen such that the cancer antigen is recombinantly expressed by the yeast cell or yeast spheroplast."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 65, wherein the yeast cell or yeast spheroplast that recombinantly expresses the cancer antigen is used to produce a yeast vehicle comprising a yeast cytoplast, a yeast ghost, or a subcellular yeast membrane extract or fraction thereof."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the yeast vehicle is from a non-pathogenic yeast."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kiuveromyces, Hansenula, Candida and Pichia. "],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein Saccharomyces is S. cerevisiae. "],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["A method to increase survival, reduce tumor burden, or inhibit tumor growth in an animal that has cancer, comprising administering to an animal a composition that increases survival of the animal or reduces tumor burden in the animal, wherein the composition comprises:\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein X6 is a proline."],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the peptide comprises an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":72,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof."],"number":73,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein a yeast cell or yeast spheroplast used to prepare the yeast vehicle was transformed with a recombinant nucleic acid molecule encoding the cancer antigen such that the cancer antigen is recombinantly expressed by the yeast cell or yeast spheroplast."],"number":74,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 74, wherein the yeast cell or yeast spheroplast that recombinantly expresses the cancer antigen is used to produce a yeast vehicle comprising a yeast cytoplast, a yeast ghost, or a subcellular yeast membrane extract or fraction thereof."],"number":75,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the yeast vehicle is from a non-pathogenic yeast."],"number":76,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kiuveromyces, Hansenula, Candida and Pichia. "],"number":77,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein Saccharomyces is S. cerevisiae. "],"number":78,"annotation":false,"claim":true,"title":false},{"lines":["A method to increase survival, reduce tumor burden, or inhibit tumor growth in an animal that has cancer, comprising administering to an animal a composition that increases survival of the animal or reduces tumor burden in the animal, wherein the composition comprises:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer, wherein the cancer antigen is EGF-R; and\nii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and 200 amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof\nwherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2—X3—X4—X5—X6;\n\n(1) wherein M is methionine;\n(2) wherein X2 is any amino acid except glycine, proline, lysine or arginine;\n(3) wherein X3 is any amino acid except methionine, lysine or arginine;\n(4) wherein X4 is any amino acid except methionine, lysine or arginine;\n(5) wherein X5 is any amino acid except methionine, lysine or arginine; and\n(6) wherein X6 is any amino acid except methionine.\n
a) a yeast vehicle; and\n
b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising:\n"],"number":79,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the yeast vehicle is a whole yeast."],"number":80,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":81,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the yeast vehicle is a whole yeast."],"number":82,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the yeast vehicle is a whole yeast."],"number":83,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the peptide consists of between two and six amino acids."],"number":84,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":85,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order:\ni) at least one cancer antigen or an immunogenic domain thereof expressed by the animal's cancer, wherein the cancer antigen is VHL (von Hippel's Lindau protein); and\nii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and 200 amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof\nwherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2—X3—X4—X5—X6;\n\n(1) wherein M is methionine;\n(2) wherein X2 is any amino acid except glycine, proline, lysine or arginine;\n(3) wherein X3 is any amino acid except methionine, lysine or arginine;\n(4) wherein X4 is any amino acid except methionine, lysine or arginine;\n(5) wherein X5 is any amino acid except methionine, lysine or arginine; and\n(6) wherein X6 is any amino acid except methionine.\n
a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras; and\n
b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the amino acid at position 12 is mutated as compared to wild-type Ras; and\n
c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras."],"number":86,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 86, wherein the peptide consists of between two and six amino acids."],"number":87,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 86, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":88,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 86, wherein the yeast vehicle is a whole yeast."],"number":89,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras."],"number":90,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 90, wherein the peptide consists of between two and six amino acids."],"number":91,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 90, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":92,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 90, wherein the yeast vehicle is a whole yeast."],"number":93,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 50, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 61 of Ras as compared to a wild-type Ras."],"number":94,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 94, wherein the peptide consists of between two and six amino acids."],"number":95,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 94, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":96,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 94, wherein the yeast vehicle is a whole yeast."],"number":97,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 94, wherein the cancer antigen further comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras."],"number":98,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 98, wherein the peptide consists of between two and six amino acids."],"number":99,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 98, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":100,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 98, wherein the yeast vehicle is a whole yeast."],"number":101,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 58, wherein the peptide consists of between two and six amino acids."],"number":102,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 58, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":103,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 58, wherein the yeast vehicle is a whole yeast."],"number":104,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 60, wherein the peptide consists of between two and six amino acids."],"number":105,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 60, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":106,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 60, wherein the yeast vehicle is a whole yeast."],"number":107,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 62, wherein the peptide consists of between two and six amino acids."],"number":108,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 62, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":109,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 62, wherein the yeast vehicle is a whole yeast."],"number":110,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the peptide consists of between two and six amino acids."],"number":111,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 70, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":112,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 79, wherein the peptide consists of between two and six amino acids."],"number":113,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 79, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1)."],"number":114,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}